Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Fosphenytoin | The serum concentration of Fosphenytoin can be decreased when it is combined with Tetrahydrofolic acid. |
| Raltitrexed | The therapeutic efficacy of Raltitrexed can be decreased when used in combination with Tetrahydrofolic acid. |
| Sulfasalazine | The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Sulfasalazine. |
| Phenytoin | The serum concentration of Phenytoin can be decreased when it is combined with Tetrahydrofolic acid. |
| Glucarpidase | The serum concentration of the active metabolites of Tetrahydrofolic acid can be reduced when Tetrahydrofolic acid is used in combination with Glucarpidase resulting in a loss in efficacy. |
| Phenobarbital | The serum concentration of Phenobarbital can be decreased when it is combined with Tetrahydrofolic acid. |
| Primidone | The serum concentration of Primidone can be decreased when it is combined with Tetrahydrofolic acid. |
| Pyrimethamine | The therapeutic efficacy of Pyrimethamine can be decreased when used in combination with Tetrahydrofolic acid. |
| Dapsone | The therapeutic efficacy of Dapsone can be decreased when used in combination with Tetrahydrofolic acid. |
| Methotrexate | The therapeutic efficacy of Methotrexate can be decreased when used in combination with Tetrahydrofolic acid. |
| Pemetrexed | The therapeutic efficacy of Pemetrexed can be decreased when used in combination with Tetrahydrofolic acid. |
| Proguanil | The therapeutic efficacy of Proguanil can be decreased when used in combination with Tetrahydrofolic acid. |
| Trimetrexate | The therapeutic efficacy of Trimetrexate can be decreased when used in combination with Tetrahydrofolic acid. |
| Piritrexim | The therapeutic efficacy of Piritrexim can be decreased when used in combination with Tetrahydrofolic acid. |
| Metoprine | The therapeutic efficacy of Metoprine can be decreased when used in combination with Tetrahydrofolic acid. |
| Iclaprim | The therapeutic efficacy of Iclaprim can be decreased when used in combination with Tetrahydrofolic acid. |
| Pralatrexate | The therapeutic efficacy of Pralatrexate can be decreased when used in combination with Tetrahydrofolic acid. |
| Aminopterin | The therapeutic efficacy of Aminopterin can be decreased when used in combination with Tetrahydrofolic acid. |
| Lometrexol | The therapeutic efficacy of Lometrexol can be decreased when used in combination with Tetrahydrofolic acid. |
| Nolatrexed | The therapeutic efficacy of Nolatrexed can be decreased when used in combination with Tetrahydrofolic acid. |
| Brodimoprim | The therapeutic efficacy of Brodimoprim can be decreased when used in combination with Tetrahydrofolic acid. |
| Cycloguanil | The therapeutic efficacy of Cycloguanil can be decreased when used in combination with Tetrahydrofolic acid. |
| Valproic acid | The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Valproic acid. |
| Colestipol | The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Colestipol. |
| Carbamazepine | The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Carbamazepine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Fluorouracil. |
| Flucytosine | The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Flucytosine. |
| Capecitabine | The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Capecitabine. |
| 5-fluorouridine | The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with 5-fluorouridine. |
| Uracil | The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Uracil. |
| Tegafur | The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Tegafur. |
| Doxifluridine | The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Doxifluridine. |
| Pafolacianine | Tetrahydrofolic acid may decrease effectiveness of Pafolacianine as a diagnostic agent. |